Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature.
Publication
, Journal Article
Zafar, FS; Richey, P; Okereke, U; Milhem, M; Abid, R; Powers, JG
Published in: Melanoma Res
February 1, 2021
Pembrolizumab is a humanized IgG4 isotype mAb that the targets and blocks the programmed cell death protein 1 receptor on lymphocytes. Its use in treating metastatic melanoma is associated with increased overall survival compared to other older immunotherapies. Several adverse effects have been noted including both systemic and cutaneous manifestations. As a relatively novel treatment option, many new cutaneous manifestations are still being observed, occurring at various times after initiation of therapy. Previously noted cutaneous adverse effects include sarcoid-like reactions, rash, and changes in preexisting lesions or scars. Here we present a case in which biopsy-proven morphea developed after completion of pembrolizumab therapy.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
Melanoma Res
DOI
EISSN
1473-5636
Publication Date
February 1, 2021
Volume
31
Issue
1
Start / End Page
98 / 100
Location
England
Related Subject Headings
- Skin Neoplasms
- Scleroderma, Localized
- Oncology & Carcinogenesis
- Neoplasm Metastasis
- Melanoma
- Lymph Nodes
- Humans
- Female
- Drug-Related Side Effects and Adverse Reactions
- Antibodies, Monoclonal, Humanized
Citation
APA
Chicago
ICMJE
MLA
NLM
Zafar, F. S., Richey, P., Okereke, U., Milhem, M., Abid, R., & Powers, J. G. (2021). Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature. Melanoma Res, 31(1), 98–100. https://doi.org/10.1097/CMR.0000000000000713
Zafar, Faraaz S., Patricia Richey, Uchenna Okereke, Mohammed Milhem, Roshan Abid, and Jennifer G. Powers. “Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature.” Melanoma Res 31, no. 1 (February 1, 2021): 98–100. https://doi.org/10.1097/CMR.0000000000000713.
Zafar FS, Richey P, Okereke U, Milhem M, Abid R, Powers JG. Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature. Melanoma Res. 2021 Feb 1;31(1):98–100.
Zafar, Faraaz S., et al. “Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature.” Melanoma Res, vol. 31, no. 1, Feb. 2021, pp. 98–100. Pubmed, doi:10.1097/CMR.0000000000000713.
Zafar FS, Richey P, Okereke U, Milhem M, Abid R, Powers JG. Morphea following treatment with pembrolizumab for melanoma with metastatic lymph nodes: case report and review of literature. Melanoma Res. 2021 Feb 1;31(1):98–100.
Published In
Melanoma Res
DOI
EISSN
1473-5636
Publication Date
February 1, 2021
Volume
31
Issue
1
Start / End Page
98 / 100
Location
England
Related Subject Headings
- Skin Neoplasms
- Scleroderma, Localized
- Oncology & Carcinogenesis
- Neoplasm Metastasis
- Melanoma
- Lymph Nodes
- Humans
- Female
- Drug-Related Side Effects and Adverse Reactions
- Antibodies, Monoclonal, Humanized